181 related articles for article (PubMed ID: 37752231)
1. The C-terminal transactivation domain of MITF interacts promiscuously with co-activator CBP/p300.
Brown AD; Lynch K; Langelaan DN
Sci Rep; 2023 Sep; 13(1):16094. PubMed ID: 37752231
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of CBP/p300 recruitment by the microphthalmia-associated transcription factor.
Brown AD; Vergunst KL; Branch M; Blair CM; Dupré DJ; Baillie GS; Langelaan DN
Biochim Biophys Acta Mol Cell Res; 2023 Oct; 1870(7):119520. PubMed ID: 37353163
[TBL] [Abstract][Full Text] [Related]
3. Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP.
Wang R; He Y; Robinson V; Yang Z; Hessler P; Lasko LM; Lu X; Bhathena A; Lai A; Uziel T; Lam LT
Mol Cancer Ther; 2018 Dec; 17(12):2543-2550. PubMed ID: 30266801
[TBL] [Abstract][Full Text] [Related]
4. β-Catenin interacts with the TAZ1 and TAZ2 domains of CBP/p300 to activate gene transcription.
Brown AD; Cranstone C; Dupré DJ; Langelaan DN
Int J Biol Macromol; 2023 May; 238():124155. PubMed ID: 36963539
[TBL] [Abstract][Full Text] [Related]
5. Structural insights into TAZ2 domain-mediated CBP/p300 recruitment by transactivation domain 1 of the lymphopoietic transcription factor E2A.
Lochhead MR; Brown AD; Kirlin AC; Chitayat S; Munro K; Findlay JE; Baillie GS; LeBrun DP; Langelaan DN; Smith SP
J Biol Chem; 2020 Mar; 295(13):4303-4315. PubMed ID: 32098872
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of MITF transcriptional activity independent of targeting p300/CBP coactivators.
Vachtenheim J; Sestáková B; Tuhácková Z
Pigment Cell Res; 2007 Feb; 20(1):41-51. PubMed ID: 17250547
[TBL] [Abstract][Full Text] [Related]
7. Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation.
Jenkins LM; Yamaguchi H; Hayashi R; Cherry S; Tropea JE; Miller M; Wlodawer A; Appella E; Mazur SJ
Biochemistry; 2009 Feb; 48(6):1244-55. PubMed ID: 19166313
[TBL] [Abstract][Full Text] [Related]
8. MITF: master regulator of melanocyte development and melanoma oncogene.
Levy C; Khaled M; Fisher DE
Trends Mol Med; 2006 Sep; 12(9):406-14. PubMed ID: 16899407
[TBL] [Abstract][Full Text] [Related]
9. Mapping the interactions of the p53 transactivation domain with the KIX domain of CBP.
Lee CW; Arai M; Martinez-Yamout MA; Dyson HJ; Wright PE
Biochemistry; 2009 Mar; 48(10):2115-24. PubMed ID: 19220000
[TBL] [Abstract][Full Text] [Related]
10. MITF and TFEB cross-regulation in melanoma cells.
Ballesteros-Álvarez J; Dilshat R; Fock V; Möller K; Karl L; Larue L; Ögmundsdóttir MH; Steingrímsson E
PLoS One; 2020; 15(9):e0238546. PubMed ID: 32881934
[TBL] [Abstract][Full Text] [Related]
11. The MITF family of transcription factors: Role in endolysosomal biogenesis, Wnt signaling, and oncogenesis.
Ploper D; De Robertis EM
Pharmacol Res; 2015 Sep; 99():36-43. PubMed ID: 26003288
[TBL] [Abstract][Full Text] [Related]
12. Structures of KIX domain of CBP in complex with two FOXO3a transactivation domains reveal promiscuity and plasticity in coactivator recruitment.
Wang F; Marshall CB; Yamamoto K; Li GY; Gasmi-Seabrook GM; Okada H; Mak TW; Ikura M
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6078-83. PubMed ID: 22474372
[TBL] [Abstract][Full Text] [Related]
13. Acetylation reprograms MITF target selectivity and residence time.
Louphrasitthiphol P; Loffreda A; Pogenberg V; Picaud S; Schepsky A; Friedrichsen H; Zeng Z; Lashgari A; Thomas B; Patton EE; Wilmanns M; Filippakopoulos P; Lambert JP; Steingrímsson E; Mazza D; Goding CR
Nat Commun; 2023 Sep; 14(1):6051. PubMed ID: 37770430
[TBL] [Abstract][Full Text] [Related]
14. Recognition of the disordered p53 transactivation domain by the transcriptional adapter zinc finger domains of CREB-binding protein.
Krois AS; Ferreon JC; Martinez-Yamout MA; Dyson HJ; Wright PE
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):E1853-62. PubMed ID: 26976603
[TBL] [Abstract][Full Text] [Related]
15. MiT/TFE Family Renal Cell Carcinoma.
Tang J; Baba M
Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672892
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for recruitment of CBP/p300 coactivators by STAT1 and STAT2 transactivation domains.
Wojciak JM; Martinez-Yamout MA; Dyson HJ; Wright PE
EMBO J; 2009 Apr; 28(7):948-58. PubMed ID: 19214187
[TBL] [Abstract][Full Text] [Related]
17. A dominant negative mutant of microphthalmia transcription factor (MITF) lacking two transactivation domains suppresses transcription mediated by wild type MITF and a hyperactive MITF derivative.
Vachtenheim J; Drdová B
Pigment Cell Res; 2004 Feb; 17(1):43-50. PubMed ID: 14717844
[TBL] [Abstract][Full Text] [Related]
18. MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma.
Kim E; Zucconi BE; Wu M; Nocco SE; Meyers DJ; McGee JS; Venkatesh S; Cohen DL; Gonzalez EC; Ryu B; Cole PA; Alani RM
Cancer Res; 2019 May; 79(10):2649-2661. PubMed ID: 30910803
[TBL] [Abstract][Full Text] [Related]
19. CBP/p300 as a co-factor for the Microphthalmia transcription factor.
Sato S; Roberts K; Gambino G; Cook A; Kouzarides T; Goding CR
Oncogene; 1997 Jun; 14(25):3083-92. PubMed ID: 9223672
[TBL] [Abstract][Full Text] [Related]
20. p300/CREB-binding protein enhances the prolactin-mediated transcriptional induction through direct interaction with the transactivation domain of Stat5, but does not participate in the Stat5-mediated suppression of the glucocorticoid response.
Pfitzner E; Jähne R; Wissler M; Stoecklin E; Groner B
Mol Endocrinol; 1998 Oct; 12(10):1582-93. PubMed ID: 9773981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
